Legg-Calvé-Perthes disease is one of the most perplexing conditions in paediatric orthopaedics. It strikes children by cutting off the blood supply to the growing femoral head, the ball of the hip joint, causing the bone tissue inside to die while the overlying cartilage initially survives. As the weakened bone continues to bear the child’s weight, it gradually loses its spherical shape, setting the stage for deformity, cartilage degeneration and, in many cases, early-onset osteoarthritis that can require joint replacement in adulthood. An estimated 20,000 to 30,000 new osteonecrosis cases are diagnosed each year in the United States, accounting for roughly ten percent of all hip arthroplasties, yet the cellular mechanisms that prevent the young bone from repairing itself have remained stubbornly obscure. A new study published in the Journal of Cellular and Molecular Medicine now offers the most direct look yet at what goes wrong inside the progenitor cells that should be rebuilding the damaged femoral head, and, remarkably, shows that the defect can be reversed with existing drugs.
The research team, working at the Korea Research Institute of Bioscience and Bioscience-affiliated laboratories, took an approach that sidesteps a long-standing obstacle in the field. Bone marrow from children with Legg-Calvé-Perthes disease is scarce and difficult to study, and even when mesenchymal stromal cells, the body’s principal skeletal progenitors, are isolated from osteonecrotic bone, they carry the imprint of a diseased, inflamed, poorly perfused tissue environment. Any abnormality observed in such cells could reflect that hostile microenvironment rather than an intrinsic flaw. To separate the two, the researchers reprogrammed skin fibroblasts from two patients with the disease, and from a healthy donor, into induced pluripotent stem cells using a non-integrating Sendai virus system that delivers the reprogramming factors OCT4, SOX2, KLF4 and c-MYC. Because skin cells can be reset to an embryonic-like state and then steered into mesenchymal stem cells under identical, standardized conditions, any difference that emerges between patient-derived and healthy cells must be written into the cells themselves rather than imposed by the tissue around them.
The quality control on this cellular reset was rigorous. The resulting induced pluripotent stem cell lines formed compact colonies with the characteristic morphology of embryonic stem cells, stained strongly for alkaline phosphatase, and expressed the canonical pluripotency markers OCT4, NANOG, TRA-1-60, TRA-1-81, SSEA-3 and SSEA-4 at levels comparable across all three lines. Quantitative PCR confirmed expression of OCT4 and REX1 in the undifferentiated state, and when the cells were allowed to spontaneously differentiate into embryoid bodies, they activated ectodermal markers such as SOX1 and PAX6, mesodermal markers including HAND1 and PDGFRA, and endodermal markers SOX7 and AFP. Immunostaining for TUJ1, NESTIN, DESMIN, alpha-SMA, FOXA2 and SOX17 confirmed protein-level differentiation into all three germ layers, and teratoma assays in immunodeficient mice produced tissues representing ectoderm, mesoderm and endoderm. G-band karyotyping showed normal diploid chromosomes in every line, ensuring that any phenotype found later was not an artefact of culture stress or genomic instability.
With validated stem cell lines in hand, the team differentiated them into induced mesenchymal stem cells using a defined, xeno-free protocol, first patterning the cells toward the mesodermal lineage for four days and then maturing them for a further seventeen days on fibronectin-coated plates. Flow cytometry confirmed that the resulting cells expressed the canonical mesenchymal markers CD73 and CD105 and lacked the haematopoietic markers CD34 and CD45, consistent with bona fide MSC identity. One subtlety stood out: the two patient-derived lines expressed CD90, a surface glycoprotein involved in adhesion and MSC immunophenotype, at only about sixty to seventy percent of the level seen in healthy donor cells, which reached roughly ninety-five percent. Proliferation rates, however, were indistinguishable between the groups, meaning the patient cells grew normally even as they showed this subtle phenotypic deviation, hinting that the real differences lay deeper, in what the cells could become rather than how fast they could multiply.
What the cells could become turned out to be the central finding. Under osteogenic induction, healthy donor cells produced abundant mineralized matrix, revealed by intense Alizarin Red S staining, and strongly upregulated the osteoblast genes RUNX2 and BGLAP. Both patient-derived lines formed dramatically fewer mineral deposits and mounted only weak induction of the same genes. Adipogenesis fared no better: healthy cells accumulated plentiful lipid droplets stained by Oil Red O and induced the adipogenic regulators PPARG and ADIPOQ, while patient cells showed markedly reduced lipid accumulation and gene induction. Chondrogenesis, assessed by Alcian Blue staining of sulfated glycosaminoglycans and by expression of SOX9 and COL2A1, was also reduced but comparatively better preserved. Crucially, this pattern of a simultaneous, broad suppression of all three mesenchymal lineages argues against the classic idea of a simple lineage shift, in which bone-forming cells are diverted into fat cells. Instead, it points to a deeper loss of overall differentiation competence within the patient-derived progenitors themselves.
The molecular culprit emerged when the researchers examined the Wnt/beta-catenin pathway, the master regulator of mesenchymal lineage commitment. Beta-catenin, the transcriptional co-activator at the heart of canonical Wnt signalling, promotes osteogenesis and chondrogenesis while restraining adipogenesis, and its intracellular abundance is normally kept in check by glycogen synthase kinase-3, which phosphorylates beta-catenin and tags it for proteasomal destruction. In the patient-derived cells, the team found a striking double abnormality. Transcripts for CTNNB1, the gene encoding beta-catenin, were significantly reduced, while GSK3B mRNA was markedly elevated. At the protein level, phosphorylation of GSK3alpha at Tyr279 and GSK3beta at Tyr216, the modifications associated with enhanced enzymatic activity, was substantially increased, reaching roughly 1.8- to 2.2-fold above healthy donor levels in the more severely affected patient line. Total beta-catenin protein and intracellular beta-catenin fluorescence were correspondingly diminished, painting a coherent picture of a kinase pushed into overdrive and a key transcriptional regulator destroyed faster than it should be.
The disease signature extended into inflammation, a domain long suspected to matter in this condition because children with active disease show elevated IL-6 and HMGB1 in synovial fluid. Even without any inflammatory stimulus, the patient-derived mesenchymal cells expressed higher baseline levels of IL6, PTGS2 and CCL2, indicating a primed inflammatory state. When the cells were challenged with IL-1beta, the patient cells responded with larger fold increases in these cytokines than healthy cells, and the Wnt target genes AXIN2 and LEF1, already slightly reduced at baseline, were driven down even further. Western blotting showed that IL-1beta pushed GSK3 phosphorylation higher in patient cells than in controls while beta-catenin, already low, declined still more. These exaggerated responses persisted after osteogenic differentiation, where patient-derived osteoblasts displayed stronger NF-kappaB phosphorylation and greater degradation of its inhibitor I-kappa-B-alpha upon inflammatory stimulation. Transcriptomic sequencing reinforced the theme, revealing enriched alterations in inflammatory signalling, extracellular matrix organization and Wnt-related regulatory pathways in both patient fibroblasts and patient-derived mesenchymal cells, with upregulation of multiple extracellular Wnt antagonists including DKK1, SFRP1, SFRP2, WIF1 and SOST.
The most striking result, and the one with the clearest translational implication, came next. When the researchers treated the patient-derived cells with lithium chloride, a long-established inhibitor of GSK3, beta-catenin fluorescence recovered to levels comparable to untreated healthy donor cells, with the rescue being strongest precisely where the deficit had been greatest. More importantly, the functional defect yielded to the same treatment. Lithium chloride substantially increased mineralized nodule formation and Oil Red O staining in both patient lines during osteogenic and adipogenic induction, and quantitative PCR confirmed that either lithium chloride or the more selective inhibitor CHIR99021 significantly boosted expression of BGLAP, RUNX2, ADIPOQ and PPARG. The differentiation programs had not been deleted; they had merely been silenced by an overactive kinase, and silencing the kinase switched them back on. This established that the mesenchymal failure in Legg-Calvé-Perthes disease reflects a reversible, kinase-dependent signalling imbalance rather than irreversible cellular damage.
The study’s authors are careful to place their findings in context. Observations in patients, such as elevated circulating leptin and increased adipose tissue within the affected femoral head, reflect systemic and tissue-level changes that arise from ischemia, inflammation and altered marrow mechanics, and the in vitro reduction in adipogenesis seen here does not contradict that clinical picture. Rather, the platform isolates the intrinsic cellular component of the disease, complementing animal models in which ischemia was surgically induced in piglets and rodents. Those models have shown that ischemia activates hypoxia-inducible factor 1-alpha and drives inflammatory and angiogenic responses, and the new human data now connect those tissue-level events to a specific, druggable intracellular node inside the progenitors that must rebuild the bone. The authors propose a reciprocal feedback loop in which inflammatory activation sustains GSK3 activity, further destabilizing beta-catenin and progressively compromising skeletal regeneration.
For a disease whose current treatments range from conservative containment to major reconstructive surgery, the prospect of a pharmacological strategy that restores the bone-building capacity of a child’s own progenitor cells is genuinely exciting. Lithium is an old drug with a well-characterized safety profile in other contexts, and the iPSC-based model developed here provides a patient-specific testing ground for optimizing GSK3-targeted regenerative therapies before they reach the clinic. Much work remains, including validating the findings in larger patient cohorts and determining how a GSK3 inhibitor could be delivered safely to the developing femoral head. But the central message stands: the cellular failure underlying a devastating childhood hip disease is not a life sentence written into the genome, but a reversible regulatory state, and with the right key, the machinery of skeletal repair can be switched back on.
Subject of Research: Reversible GSK3/beta-catenin dysregulation in patient-derived iPSC-mesenchymal stem cells from children with Legg-Calvé-Perthes disease
Article Title: Patient‐Derived iPSC‐MSC Modelling Reveals Reversible GSK3‐Mediated Suppression of Mesenchymal Lineage Differentiation in Legg‐Calvé‐Perthes Disease
Article References: Seol, B., Lim, H. J., Song, C. L., Lee, J., & Cho, Y. S. (2026). Patient‐Derived iPSC ‐ MSC Modelling Reveals Reversible GSK3 ‐Mediated Suppression of Mesenchymal Lineage Differentiation in Legg‐Calvé‐Perthes Disease. Journal of Cellular and Molecular Medicine, 30(17), Article e71350. https://doi.org/10.1111/jcmm.71350
Image Credits: AI Generated
DOI: 10.1111/jcmm.71350
Keywords: Legg-Calvé-Perthes disease, induced pluripotent stem cells, mesenchymal stem cells, GSK3, beta-catenin, Wnt signalling, osteonecrosis, osteogenesis, inflammation, lithium chloride, CHIR99021, paediatric orthopaedics
Cite Scienmag News
APA
MLA
Chicago
Drew Townsend. (September 27, 2026). Reprogramming Patient Cells Reveals a Reversible Signalling Flaw Behind a Childhood Hip Disease. Scienmag. https://scienmag.com/reprogramming-patient-cells-reveals-a-reversible-signalling-flaw-behind-a-childhood-hip-disease/
Drew Townsend. “Reprogramming Patient Cells Reveals a Reversible Signalling Flaw Behind a Childhood Hip Disease.” Scienmag, 27 September 2026, https://scienmag.com/reprogramming-patient-cells-reveals-a-reversible-signalling-flaw-behind-a-childhood-hip-disease/. Accessed 27 September 2026.
Drew Townsend. “Reprogramming Patient Cells Reveals a Reversible Signalling Flaw Behind a Childhood Hip Disease.” Scienmag. September 27, 2026. https://scienmag.com/reprogramming-patient-cells-reveals-a-reversible-signalling-flaw-behind-a-childhood-hip-disease/
Copy citation
Download RIS
Tags: beta-cateninblood supply to femoral headbone tissue necrosiscartilage preservationcellular mechanisms of bone repairchildhood hip diseaseCHIR99021drug repurposing for bone regenerationGSK3induced pluripotent stem cellsinflammationLegg-Calvé-Perthes diseaselithium chloridemesenchymal stem cellsosteoarthritis developmentosteogenesisosteonecrosispaediatric orthopaedicsprogenitor cell dysfunctionreversible signaling pathwaystem cell reprogramming in orthopaedicsWnt signalling
